Table 1 Characteristics of the studied drugs
From: Adoption of new drugs by physicians: a survival analysis
Drug | Launching | Degree of therapeutic Innovation* | Approved indications | Cost/DDD | Alternatives (cost/DDD) |
|---|---|---|---|---|---|
Cefditoren | Sep-04 | No therapeutic innovation | Pneumonia, exacerbation of chronic bronchitis, pharyngitis, tonsillitis, skin infections | €4.47 -6.26 | Amoxicillin-clavulanate (€0.68) Cefuroxime axetil (€2.27) |
Duloxetine | Dec-05 | No therapeutic innovation | Neuropathic pain, depresión, generalised anxiety disorder (from jul-08) | €1.99 | Amitriptyline (€0.11) Fluoxetine (€0.24) Paroxetine (€0.79) |
Etoricoxib | Jul-04 | No therapeutic innovation | Osteoarthritis, rheumatoid artritis, acute gouty artritis, ankylosing spondylitis (from sep-08) | €1.74 | Ibuprofen (€0.24) Diclofenac (€0.17) Naproxen (€0.38) |
Ezetimibe | Mar-04 | Insufficient evidence | Primary hypercholesterolaemia, homozygous familial hypercholesterolaemia, homozygous sitosterolaemia | €1.91 | |
Levocetirizine | Apr-03 | No therapeutic innovation | Allergic rhinitis, chronic idiopathic urticaria | €0.56 | Cetirizine (€0.29) |
Olmesartan | May-04 | No therapeutic innovation | Hypertension | €0.92 | Losartan (€0.92) Enalapril (€0.13) |
Pregabalin | Jan-05 | No therapeutic innovation | Neuropathic pain, epilepsy, generalised anxiety disorder (from mar-06) | €2.57 | Gabapentin (€0.19) Amitriptyline (€0.11) |
Tiotropium | Jan-03 | Modest therapeutic innovation | Chronic obstructive pulmonary disease | €1.91 | Ipratropium (€0.28) |